Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-human CCL24 monoclonal antibody (CM-101)
Anti-human CCL24 monoclonal antibody · 1 trial · 1 indication
Number of subjects with treatment-emergent adverse events (any, related, serious, and severe) - Safety-related endpoint
Number of subjects with treatment-emergent adverse events (any, related, serious, and severe) - Safety-related endpoints
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | EXPERIMENTAL | Anti-human CCL24 monoclonal antibody CM-101 Intravenous Infusion over 60 minutes (±5 minutes) |
| Placebo | PLACEBO_COMPARATOR | Placebo - intravenous infusion |
| Name | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | BIOLOGICAL | Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes) |
| Placebo | OTHER | Placebo - intravenous infusion |
Inclusion Criteria: * Subjects with diagnosis of large duct PSC of more than 24 weeks' duration * Subjects that have no significant clinical concern for cholangiocarcinoma based on clinical, laboratory or imaging findings * Subjects with serum Alkaline phosphatase (ALP) greater than 1.5 × Upper lim...
Anti-human CCL24 monoclonal antibody is being developed for the treatment of primary sclerosing cholangitis, a chronic liver disease. It is an investigational therapy and has not been approved for any indication. The clinical program has focused on patients with primary sclerosing cholangitis.
Anti-human CCL24 monoclonal antibody targets CCL24, a chemokine also known as eotaxin-2. By binding to CCL24, the antibody is designed to block its activity. CCL24 is involved in inflammatory and fibrotic processes, which are relevant to primary sclerosing cholangitis.
Anti-human CCL24 monoclonal antibody is being developed by Chemomab Therapeutics Ltd., which trades under the ticker CMMB. The company is advancing the antibody as a potential treatment for primary sclerosing cholangitis.
Anti-human CCL24 monoclonal antibody is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory agency. The Phase 2 program has been conducted in patients with primary sclerosing cholangitis.
Anti-human CCL24 monoclonal antibody has been studied in the Phase 2 SPRING study, registered as NCT04595825. The trial enrolled 77 patients with primary sclerosing cholangitis across the United States, Germany, Israel, Spain, and the United Kingdom. It was randomized, double-blind, and placebo-controlled, and it is now completed.
Yes, anti-human CCL24 monoclonal antibody is also known as CM-101. CM-101 is the development code used by Chemomab Therapeutics Ltd. for this monoclonal antibody. Both names refer to the same investigational therapy being studied in primary sclerosing cholangitis.